Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.30 -4.15%

-$0.41 today

Market cap
$192.17M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.17M

Average 0.26M

RNAC Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Cartesian Therapeutics, Inc.NASDAQ: RNAC

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was -$9.19M.

Context

  • Income tax expense amounted to 328.7% of revenue in FY2025, up 327.9 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$2.3M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$9.19M-3303.1% YoY
LTMMar 2026
-$9.19M-3303.1% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-3303.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(9.19M) USD
Year-over-year change
-3303.1%

Income Tax Expense vs competitors

How RNAC compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3303.1% is the lowest of 6, against a peer median of +47.0%.
  • Income tax expense amounts to 517.9% of revenue for RNAC, versus a peer median of 0.5%.
RNAC Competitors
Income Tax Expense for RNAC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$169K USD+47.0%+80.6%286.4%
MDWDMediWound Ltd.LTM Mar 2026$147K USD+250.0%+29.4%1.0%
FENCFennec Pharmaceuticals Inc.LTM Mar 2026$106K USD-71.0%—0.2%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$30.19K USD+7553.1%——
IVAInventiva S.A.FY2025€22K EUR-93.0%—0.5%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$0 USD——0.0%
NAUTNautilus Biotechnology, Inc.LTM Mar 2026$0 USD———
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$0 USD———
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$9.19M USD-3303.1%—517.9%
Peer median (excluding RNAC) —+47.0%+55.0%0.5%

Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Intrinsic Alpha fair value

Locked

Current Price

$6.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.